{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/polycystic-ovary-syndrome/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"483e27e7-00c5-5c3a-b61b-d00edbcafdd7","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field 3510ba10-d1f7-4258-bf7e-656f035b2161 --><h2>What investigations should I arrange?</h2><!-- end field 3510ba10-d1f7-4258-bf7e-656f035b2161 -->","summary":"","htmlStringContent":"<!-- begin item cf5777aa-6edf-421f-af5d-247e65e82b61 --><!-- begin field 965478c8-8623-463a-9c04-d222b9d6aa12 --><ul><li><strong>Measure total testosterone</strong> — this is normal to moderately elevated in women with polycystic ovary syndrome (PCOS).</li><li><strong>Measure sex hormone-binding globulin (SHBG)</strong> — this is normal to low in women with PCOS and provides a surrogate measurement of the degree of hyperinsulinaemia.</li><li><strong>Calculate free androgen index</strong> (100 multiplied by the total testosterone value divided by the SHBG value) to assess the amount of physiologically active testosterone present — this is normal or elevated in women with PCOS<strong> </strong>(the normal range is usually less than 5, but this depends on local laboratories). </li><li><strong>Measure the following to rule out other causes of oligomenorrhoea and amenorrhoea </strong>(such as premature ovarian failure, hypothyroidism, and hyperprolactinaemia):<ul><li>Luteinizing hormone and follicle-stimulating hormone — may be increased in women with premature ovarian failure, and decreased in women with hypogonadotropic hypogonadism.</li><li>Prolactin (normal range is less than 500 mU/L) — may be mildly elevated in women with PCOS.</li><li>Thyroid-stimulating hormone (normal range 0.4–4.5 mU/L).</li></ul></li><li><strong>Refer adults for ultrasound scan </strong><strong>to look for the classic picture of polycystic ovaries</strong><strong> </strong>(unless the diagnosis of PCOS is obvious on clinical and biochemical grounds). <ul><li>Polycystic ovaries on ultrasound are defined as the presence of 12 or more follicles in at least one ovary (measuring 2–9 mm diameter) or increased ovarian volume (greater than 10 cm<sup>3</sup>).</li><li>Be aware that polycystic ovaries do not have to be present to make the diagnosis of PCOS, and the finding of polycystic ovaries does not alone establish the diagnosis.</li><li><strong>Ultrasound scan should not be used for the diagnosis of PCOS in adolescents.</strong></li></ul></li><li><strong>Exclude <a class=\"topic-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/diagnosis/differential-diagnosis/\">other causes</a> of hyperandrogenism (such as late-onset congenital adrenal hyperplasia, Cushing's syndrome, or an androgen-secreting tumour) if:</strong><ul><li>There are signs of virilization, for example, deep voice, reduced breast size, increased muscle bulk, and clitoral hypertrophy.</li><li>There is rapidly progressing hirsutism (less than 1 year between hirsutism being noticed and seeking medical advice).</li><li>The total testosterone level is significantly elevated (greater than 5 nmol/l or more than twice the upper limit of normal reference range).</li></ul></li></ul><!-- end field 965478c8-8623-463a-9c04-d222b9d6aa12 --><!-- end item cf5777aa-6edf-421f-af5d-247e65e82b61 -->","topic":{"id":"daaf23b6-59bf-5fa9-96d9-6d98f028d2bd","topicId":"90f70ae3-1caf-4e74-8397-cf2655cfb10c","topicName":"Polycystic ovary syndrome","slug":"polycystic-ovary-syndrome","lastRevised":"Last revised in September 2018","chapters":[{"id":"6f41b5a4-2e7e-5469-91c8-15331570cb8c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5ad66803-f217-58c6-ad92-d9db6491cb26","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"132cf0f7-983a-59b8-aa99-10f350089b7c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d45a2f22-c9b6-5ee0-afb6-8ae3d0397d9f","slug":"changes","fullItemName":"Changes"},{"id":"e3852569-27c3-5e63-ab2f-2b92dcfe5262","slug":"update","fullItemName":"Update"}]},{"id":"f1fe2489-77fe-5403-977f-d3603e5bae1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"048d9ada-61af-59a9-971e-42aed733010a","slug":"goals","fullItemName":"Goals"},{"id":"845cd360-b1c4-50ee-a60f-5ec2ce05b2b8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6bed55f9-2ee7-578e-8770-b9a5e2053955","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"0afb7a34-d84c-5ad9-bcc3-0dc5345cd2b8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7587b9f-e03a-5ba0-b6c5-173412097eb9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b7749edb-c354-5cb9-adc7-04cbe456d37d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"390c9f6a-9392-5672-8a5d-2945f5be467d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5ae79977-6f68-54e7-bae5-d3a83aa4bad7","slug":"definition","fullItemName":"Definition"},{"id":"86ec422e-1b3a-5c12-b4df-64886e831aea","slug":"causes","fullItemName":"Causes"},{"id":"87943c47-132e-5d7b-bba7-9f5fd8d2fdd8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"fd9eddac-eb60-523a-9a51-e94719b6fef4","slug":"complications","fullItemName":"Complications"},{"id":"104e8e2a-4d4d-5fc6-b68f-5337dd3ccc87","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"26e7fb06-0e4c-5c05-aea8-632061b95e52","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6f9e9e17-1a64-5142-813c-89d3dc869c6d","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"483e27e7-00c5-5c3a-b61b-d00edbcafdd7","slug":"investigations","fullItemName":"Investigations"},{"id":"6a10f0bc-d2b9-504d-beb4-a033a4cfb16b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"82ce27d1-1cdc-5a75-8d26-8bbb3d8d62d7","fullItemName":"Management","slug":"management","subChapters":[{"id":"5c7d454c-e837-5db4-96b6-d7259cedcbb1","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"762c879d-8353-5b98-98e3-cd5e9dd9238e","slug":"management-adolescents","fullItemName":"Scenario: Management - adolescents"}]},{"id":"980e12cc-a3a7-5006-9004-9a3817403978","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8c324c3d-d93a-5a1b-9a8f-070221373b1a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0096e783-16f8-5f5a-9660-d3685b777a10","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"af33ae46-9b14-5c06-98b3-689fc80c683f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"61bd6f68-6b5a-5980-aec9-07bcbf6dc232","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3d02f180-e5e5-5a10-a991-a415041c663f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"17c9b913-2bf1-5468-a926-0f8643a69cc1","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"696b4fff-16f7-5d8a-a5d1-da81a7a53ffc","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"26e7fb06-0e4c-5c05-aea8-632061b95e52","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"a5f1fe07-ac7f-591f-97cd-585da7822415","slug":"basis-for-recommendation-6cb","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field eab59b13-f270-44a1-8adf-47bcd7207671 --><h3>Basis for recommendation</h3><!-- end field eab59b13-f270-44a1-8adf-47bcd7207671 -->","summary":null,"htmlStringContent":"<!-- begin item 6cb8dd55-cef6-4a78-89cd-d396218f71f7 --><!-- begin field 9b63f98d-6666-45d3-af53-917ad6f69cb6 --><p>These recommendations are based on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>], <em>The polycystic ovary syndrome: a position statement from the European Society of Endocrinology </em>(ESE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>], the<em> I</em><em>nternational evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> issued by the International Polycystic Ovary Syndrome (PCOS) Network [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>], evidence from a small study on the biological variation of testosterone and sex hormone-binding globulin (SHBG) in PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Jayagopal et al, 2003</a>], and expert opinion in a review article on PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Duncan, 2014</a>] and in relevant chapters of a textbook on the management of PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Dewailly, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Homburg, 2010</a>].</p><h4>Total testosterone, SHBG, and free androgen index (FAI)</h4><ul><li>FAI (calculated by the ratio between total testosterone and SHBG) is the recommended baseline biochemical test for the evaluation of hyperandrogenism. It provides a simple assessment of the amount of physiologically active testosterone present [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]. </li><li>SHBG is a surrogate marker of insulin resistance and androgen excess that predicts the susceptibility to develop metabolic syndrome and gestational diabetes in women with PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Conway, 2014</a>].<ul><li>Insulin suppresses SHBG [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Jayagopal et al, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Homburg, 2010</a>].</li><li>If the SHBG level is low despite an apparently normal total testosterone level, the amount of free testosterone (which is the bioactive form) may be increased, therefore elevating the FAI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Dewailly, 2010</a>].</li></ul></li></ul><h4>Tests to rule out other causes of oligomenorrhoea and amenorrhoea </h4><ul><li>Measurement of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are essential in the diagnosis of other conditions that may present with amenorrhoea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Balen, 2010</a>].</li><li>Prolactin levels may be normal or mildly elevated in PCOS [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Homburg, 2010</a>]. </li><li>Although thyroid-stimulating hormone is a useful screening test, the incidence of thyroid dysfunction among women with hyperandrogenism is no higher than that in women without hyperandrogenism who are of reproductive age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Homburg, 2010</a>].</li></ul><h4>Ultrasound scan</h4><ul><li>The 2003 Rotterdam Consensus Workshop Group defines polycystic ovaries as the presence of 12 or more follicles (measuring 2–9 mm in diameter) in one or both ovaries and/or increased ovarian volume (more than 10 cm<sup>3</sup>) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004</a>]. However, it should be noted that polycystic ovaries do not have to be present to make the diagnosis, and the finding of polycystic ovaries does not alone establish the diagnosis.<ul><li>It is estimated that 20% of women will have polycystic ovaries on an ultrasound scan [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">Duncan, 2014</a>].</li></ul></li><li>According to the <em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>]:<ul><li>In women with irregular menstrual cycles and hyperandrogenism, an ultrasound scan is not necessary for PCOS diagnosis, although it can be used to identify the complete PCOS phenotype.</li><li>Ultrasound scan should not be used for the diagnosis of PCOS in those with a gynaecological age of less than 8 years (less than 8 years after menarche) due to the high incidence of multi-follicular ovaries in this life stage.</li></ul></li></ul><h4>Excluding differential diagnoses</h4><ul><li>The RCOG advises that the diagnosis of PCOS can only be made when other causes for irregular menstrual cycles, such as thyroid dysfunction, acromegaly, or hyperprolactinaemia, have been excluded if there is clinical suspicion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">RCOG, 2014</a>]. </li><li>Expert opinion in the <em>International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018</em> is that exclusion of thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia is recommended with further evaluation recommended in those with amenorrhea and more severe clinical features, including consideration of hypogonadotropic hypogonadism, Cushing’s disease, or androgen-producing tumours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/polycystic-ovary-syndrome/references/\">International PCOS Network, 2018</a>].</li></ul><!-- end field 9b63f98d-6666-45d3-af53-917ad6f69cb6 --><!-- end item 6cb8dd55-cef6-4a78-89cd-d396218f71f7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}